MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 578137 | Name: Nicardipine phosphate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Nicardipine is a medication used to treat high blood pressure and angina. It belongs to the dihydropyridine class of calcium channel blockers. Nicardipine is a dihydropyridine calcium-channel blocking agent used for the treatment of vascular disorders such as chronic stable angina, hypertension, and Raynaud's phenomenon. It is available in oral and intravenous formulations

Chemical Structure

Nicardipine phosphate
Nicardipine phosphate
CAS#156880-36-3 (phosphate)

Theoretical Analysis

MedKoo Cat#: 578137

Name: Nicardipine phosphate

CAS#: 156880-36-3 (phosphate)

Chemical Formula: C26H32N3O10P

Exact Mass: 577.1825

Molecular Weight: 577.53

Elemental Analysis: C, 54.07; H, 5.59; N, 7.28; O, 27.70; P, 5.36

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
55985-32-5 (free base) 54527-84-3 (HCl) 156880-36-3 (phosphate)
Synonym
Nicardipine phosphate
IUPAC/Chemical Name
3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 2-(methyl(phenylmethyl)amino)ethyl ester, phosphate
InChi Key
SPIHVFWWUWZMFE-UHFFFAOYSA-N
InChi Code
InChI=1S/C26H29N3O6.H3O4P/c1-17-22(25(30)34-4)24(20-11-8-12-21(15-20)29(32)33)23(18(2)27-17)26(31)35-14-13-28(3)16-19-9-6-5-7-10-19;1-5(2,3)4/h5-12,15,24,27H,13-14,16H2,1-4H3;(H3,1,2,3,4)
SMILES Code
O=C(C1=C(C)NC(C)=C(C(OCCN(C)CC2=CC=CC=C2)=O)C1C3=CC=CC([N+]([O-])=O)=C3)OC.O=P(O)(O)O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 577.53 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Samaniego EA, Dabus G, Generoso GM, Tari-Capone F, Fuentes K, Linfante I. Postpartum cerebral angiopathy treated with intra-arterial nicardipine and intravenous immunoglobulin. J Neurointerv Surg. 2013 May;5(3):e12. doi: 10.1136/neurintsurg-2011-010220. Epub 2012 Feb 19. Review. PubMed PMID: 22345147. 2: Peacock WF 4th, Hilleman DE, Levy PD, Rhoney DH, Varon J. A systematic review of nicardipine vs labetalol for the management of hypertensive crises. Am J Emerg Med. 2012 Jul;30(6):981-93. doi: 10.1016/j.ajem.2011.06.040. Epub 2011 Sep 9. Review. PubMed PMID: 21908132. 3: Lele A, Lyon T, Pollack A, Husmann K, Reeves A. Intra-arterial nicardipine for the treatment of cerebral vasospasm in postpartum cerebral angiopathy: a case study and review of literature. Int J Neurosci. 2011 Oct;121(10):537-42. doi: 10.3109/00207454.2011.598980. Epub 2011 Aug 4. Review. PubMed PMID: 21812738. 4: Habibzadeh MR, Thai H, Movahed MR. Prophylactic intragraft injection of nicardipine prior to saphenous vein graft percutaneous intervention for the prevention of no-reflow: a review and comparison to protection devices. J Invasive Cardiol. 2011 May;23(5):202-6. Review. PubMed PMID: 21562350. 5: Nij Bijvank SW, Duvekot JJ. Nicardipine for the treatment of severe hypertension in pregnancy: a review of the literature. Obstet Gynecol Surv. 2010 May;65(5):341-7. doi: 10.1097/OGX.0b013e3181e2c795. Review. PubMed PMID: 20591204. 6: Vadhera RB, Pacheco LD, Hankins GD. Acute antihypertensive therapy in pregnancy-induced hypertension: is nicardipine the answer? Am J Perinatol. 2009 Aug;26(7):495-9. doi: 10.1055/s-0029-1214251. Epub 2009 Apr 24. Review. PubMed PMID: 19396743. 7: Amenta F, Lanari A, Mignini F, Silvestrelli G, Traini E, Tomassoni D. Nicardipine use in cerebrovascular disease: a review of controlled clinical studies. J Neurol Sci. 2009 Aug 15;283(1-2):219-23. doi: 10.1016/j.jns.2009.02.335. Epub 2009 Mar 20. Review. PubMed PMID: 19303080. 8: Amenta F, Tomassoni D, Traini E, Mignini F, Veglio F. Nicardipine: a hypotensive dihydropyridine-type calcium antagonist with a peculiar cerebrovascular profile. Clin Exp Hypertens. 2008 Nov;30(8):808-26. doi: 10.1080/10641960802580190. Review. PubMed PMID: 19021030. 9: Hoh BL, Ogilvy CS. Endovascular treatment of cerebral vasospasm: transluminal balloon angioplasty, intra-arterial papaverine, and intra-arterial nicardipine. Neurosurg Clin N Am. 2005 Jul;16(3):501-16, vi. Review. PubMed PMID: 15990041. 10: Fischell TA, Maheshwari A. Current applications for nicardipine in invasive and interventional cardiology. J Invasive Cardiol. 2004 Aug;16(8):428-32. Review. PubMed PMID: 15282420. 11: Kouoh F, Gressier B, Dine T, Luyckx M, Brunet C, Ballester L, Cazin JC. Antioxidant effects and anti-elastase activity of the calcium antagonist nicardipine on activated human and rabbit neutrophils--a potential antiatherosclerotic property of calcium antagonists? Cardiovasc Drugs Ther. 2002 Dec;16(6):515-20. Review. PubMed PMID: 12766385. 12: Nicardipine. Dimens Crit Care Nurs. 2000 Nov-Dec;19(6):25. Review. PubMed PMID: 11998053. 13: Zannad F. Concomitant diseases in elderly hypertensives: the position of nicardipine. J Hypertens Suppl. 1996 Oct;14(3):S37-40. Review. PubMed PMID: 9120665. 14: Tobias JD. Nicardipine: applications in anesthesia practice. J Clin Anesth. 1995 Sep;7(6):525-33. Review. PubMed PMID: 8534474. 15: Sy J, Vitarelli A, Gheorghiade M. Nicardipine in heart failure: distinguishing its acute beneficial from its chronic effects. Minerva Cardioangiol. 1993 Nov;41(11):535-41. Review. PubMed PMID: 8127455. 16: Frampton JE, Faulds D. Nicardipine. A review of its pharmacology and therapeutic efficacy in older patients. Drugs Aging. 1993 Mar-Apr;3(2):165-87. Review. Erratum in: Drugs Aging 1996 Jul;9(1):36. PubMed PMID: 8477149. 17: Lambert CR. Combination therapy with nicardipine and beta-adrenergic blockade for angina pectoris. Clin Cardiol. 1992 Apr;15(4):231-4. Review. PubMed PMID: 1348670. 18: Chauveau D, Houillier P, Azizi M, Sassano P, Guyenne TT, Jeunemaître X, Plouin PF, Corvol P. [Use of intravenous nicardipine for the diagnosis of renovascular hypertension]. Arch Mal Coeur Vaiss. 1991 Aug;84(8):1171-5. Review. French. PubMed PMID: 1953265. 19: Whiting RL, Dow RJ, Graham DJ, Mroszczak EJ. An overview of the pharmacology and pharmacokinetics of nicardipine. Angiology. 1990 Nov;41(11 Pt 2):987-91. Review. PubMed PMID: 2248427. 20: Fifer MA, Aroney CN, Semigran MJ, Herrmann HC, Dec GW, Boucher CA. Techniques for assessing inotropic effects of drugs in patients with heart failure: application to the evaluation of nicardipine. Am Heart J. 1990 Feb;119(2 Pt 2):451-6. Review. PubMed PMID: 2405615.